Research & Technology
The cMet Targeted Agents Platform
The foundation technology of EM Imaging revolves around a common platform platform technology with 3 key components:
- Peptide-based binder that allows specific targeting of disease process.
- Carrier backbone or pharmacokinetic modulator, coupled to a targeting agent or linker to improve bioavailability/binding affinity and stability.
- Fluorescent reporter or radionuclide to allow visualisation and/or therapy.
EM Imaging has a portfolio of agents addressing a number of unmet medical needs. Agents progressed to date have been found to be safe, tolerable, soluble, specific, sensitive and selective.
